

Technical Data Sheet



InVivoSIM bispecific anti-human CD3 x CD20 (Epcoritamab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: SIMB0094
Clone: Epcoritamab
Isotype: Human IgG1
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Reported Applications: *in vivo* functional assays
in vitro functional assays
ELISA
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Purity: ≥95%
Determined by SDS-PAGE
Sterility: 0.2 μm filtration
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein A
RRID:
Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Epcoritamab biosimilar antibody uses the same variable regions as the therapeutic antibody Epcoritamab, making it ideal for research use. Epcoritamab is a full-length bispecific IgG1 antibody that simultaneously targets human CD3 on T cells and human CD20 on B cells. By engaging CD3 and CD20, Epcoritamab redirects and activates T cells against malignant B cells, promoting synapse formation, T-cell activation, cytokine release, and targeted tumor-cell killing. Unlike earlier bispecific formats, this IgG-based architecture provides extended half-life, efficient T-cell engagement, and potent *in vivo* activity. Clinically, Epcoritamab has demonstrated significant efficacy in relapsed or refractory B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), and works through direct T-cell-mediated cytotoxicity rather than Fc-dependent mechanisms. This Epcoritamab biosimilar is well suited for investigating T-cell redirection, CD3/CD20 synapse biology, B-cell malignancies, immune-cell cytotoxicity, and the mechanistic basis of bispecific antibody therapies.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/simb0094?bxcs=9k1b3a#tab_references or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC